Reviva Pharmaceuticals Holdings, Inc. Net Income (Loss) Available to Common Stockholders, Basic
Reviva Pharmaceuticals Holdings, Inc. (RVPH) reported Net Income (Loss) Available to Common Stockholders, Basic of -$350.91 thousand for the 3-month period ending 2020-11-30, per its 10-Q filed 2021-01-14.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2021-01-14
- Reviva Pharmaceuticals Holdings, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2020-11-30 was -$350.91K.
- Reviva Pharmaceuticals Holdings, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2020-08-31 was -$523.24K.
- Reviva Pharmaceuticals Holdings, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2020-05-31 was -$237.50K.
- Reviva Pharmaceuticals Holdings, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2020-02-29 was -$331.09K.
- Reviva Pharmaceuticals Holdings, Inc. net income (loss) available to common stockholders, basic for fiscal 2020 was -$545.63K.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 2 month | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 5 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 8 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 11 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|---|---|---|---|---|
| 2020-11-30 | -$350.91K 10-Q · filed 2021-01-14 | -$874.15K derived: sum of 2 quarters · filed 2021-01-14 | -$1.11M 10-Q · filed 2021-01-14 | -$1.44M derived: sum of 4 quarters · filed 2021-01-14 | |||||
| 2020-08-31 | -$523.24K 10-Q · filed 2020-10-14 | -$758.59K 10-Q · filed 2020-10-14 | -$1.09M derived: sum of 3 quarters · filed 2020-10-14 | -$1.23M derived: sum of 4 quarters · filed 2021-01-14 | |||||
| 2020-05-31 | -$237.50K 10-Q · filed 2020-07-07 | -$568.60K derived: sum of 2 quarters · filed 2020-07-07 | -$701.91K derived: sum of 3 quarters · filed 2021-01-14 | -$756.97K derived: sum of 4 quarters · filed 2021-01-14 | |||||
| 2020-02-29 | -$331.09K derived: 10-K 12 month − 10-Q 9 month · filed 2020-05-04 | -$464.41K derived: sum of 2 quarters · filed 2021-01-14 | -$519.47K derived: sum of 3 quarters · filed 2021-01-14 | -$545.63K 10-K · filed 2020-05-04 | |||||
| 2019-11-30 | -$133.32K 10-Q · filed 2021-01-14 | -$188.37K derived: sum of 2 quarters · filed 2021-01-14 | -$214.54K 10-Q · filed 2021-01-14 | ||||||
| 2019-08-31 | -$55.06K 10-Q · filed 2020-10-14 | -$82.78K 10-Q · filed 2020-10-14 | |||||||
| 2019-05-31 | -$28.05K 10-Q · filed 2020-07-07 | ||||||||
| 2019-02-28 | -$76.68K 10-K · filed 2020-05-04 | ||||||||
| 2018-11-30 | -$43.40K 10-Q · filed 2020-01-10 | -$43.40K 10-Q · filed 2019-01-09 | -$43.65K derived: sum of 2 quarters · filed 2020-01-10 | -$56.98K 10-Q · filed 2020-01-10 | |||||
| 2018-08-31 | -$250.00 10-Q · filed 2019-10-08 | -$13.59K 10-Q · filed 2019-10-08 | |||||||
| 2018-05-31 | -$13.34K 10-Q · filed 2019-07-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |